Paul W. Noble, MD

Activity Chair

Paul W. Noble, MD

  • Professor and Chair, Department of Medicine
  • Director, Women's Guild Lung Institute
  • Cedars-Sinai Medical Center
  • Los Angeles, CA

Tuesday, October 31, 2017

Sheraton Centre Toronto Hotel
Osgoode Ballroom East, Lower Concourse Level
Toronto, Ontario, Canada

  • 5:30 am – 6:00 am
  • Registration and Breakfast
  • 6:00 am – 7:00 am
  • CME-certified Activity

Program Overview

Diffuse interstitial lung disease (ILD) is an umbrella term that comprises a broad range of related conditions causing shortness of breath and cough. Idiopathic pulmonary fibrosis (IPF), is a chronic, progressive, fibrotic lung disease of unknown cause and is associated with comorbidities, including pulmonary hypertension. The historical standard of care for IPF is oxygen supplementation, management of comorbidities, and lung transplantation. The therapeutic landscape for IPF management has evolved with the US Food and Drug Administration’s approval of 2 novel therapeutic agents. This CME activity will assess recent clinical advances regarding the use of available and emerging therapies, including mono- and combination therapy, for the management of IPF.

Copyright © Vindico Medical Education | Privacy Policy
856.994.9400 | 6900 Grove Road, Building 100 | Thorofare, New Jersey 08086
A Wyanoke Group Company